Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
Status:
Completed
Trial end date:
2021-08-15
Target enrollment:
Participant gender:
Summary
The proposed study will be a 24-week, randomized, double-blind, multi-site,
placebo-controlled study in volunteers with late mild cognitive impairment (MCI) or early
dementia due to Alzheimer's disease (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Amylyx Pharmaceuticals Inc.
Collaborators:
Alzheimer's Association Alzheimer's Drug Discovery Foundation Alzheimer’s Drug Discovery Foundation